AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04500626
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
Trial: NCT05848739
Drug: Lonsurf & bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
Trial: NCT04997317
Drug: 177Lu-DOTA-JR11 (Phase I/II)
RxNorm normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
Trial: NCT05712460
Drug: sisunatovir
RxNorm normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
Trial: NCT05679388
Drug: Relugolix Pill
RxNorm normalized name: relugolix Pill
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
Trial: NCT05679388
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
Trial: NCT05679388
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug used to treat fungal infections.
Trial: NCT04880980
Drug: Terbinafine Pill
RxNorm normalized name: terbinafine Pill
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
Trial: NCT04880980
Drug: Itraconazole capsule
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
Trial: NCT06791031
Drug: inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group.
Trial: NCT02955446
Drug: PF-03084014
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
Trial: NCT05672667
Drug: intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin given by intravenous route
Trial: NCT05672667
Drug: intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin given by intranasal administration
Trial: NCT06389201
Drug: HCQ
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
Trial: NCT06784557
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High intensity HMG-CoA reductase inhibitor
Trial: NCT06784557
Drug: Atorvastatin 20mg+Ezetimibe 10mg
RxNorm normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
Trial: NCT04938882
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT04938882
Drug: Compound lidocaine at low concentration
RxNorm normalized name: rose bengal AT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT04938882
Drug: Compound lidocaine at high concentration
RxNorm normalized name: rose bengal AT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT06529536
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus is administered to all patients post SOT at RCH
Trial: NCT05138653
Drug: CVL-354
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution/suspension
Trial: NCT05138653
Drug: CVL-354
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT05093270
Drug: BGB-23339
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a tablet
Trial: NCT05904886
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Trial: NCT05904886
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Trial: NCT05904886
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
Trial: NCT05804708
Drug: GH001
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH001 is administered via inhalation
Trial: NCT05954312
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05954312
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT05296512
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
Trial: NCT05296512
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib.
Trial: NCT05946564
Drug: Pioglitazone (ACTOS®)
RxNorm normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
Trial: NCT05946564
Drug: Placebo of Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
Trial: NCT06790888
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
Trial: NCT06784388
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
Trial: NCT06788171
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.
Trial: NCT06788171
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
Trial: NCT06788171
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab: 200mg, d1, q3w, 6 cycles.
Trial: NCT05306041
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
Trial: NCT05306041
Drug: PHESGO
RxNorm normalized name: Phesgo
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
Trial: NCT05551117
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg once daily
Trial: NCT05551117
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg daily
Trial: NCT06549634
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration
Trial: NCT04700124
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
Trial: NCT04700124
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
Trial: NCT05241613
Drug: AC176
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AC176 will be given orally (PO) on a 28-day cycle.
Trial: NCT05908916
Drug: AtezoBev with combined radiotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.
Trial: NCT06463665
Drug: Platinum chemotherapy: carboplatin or cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered according to local practice.
Trial: NCT06463665
Drug: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered according to local practice.
Trial: NCT06463665
Drug: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered according to local practice.
Trial: NCT06463665
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered according to local practice.
Trial: NCT06133062
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
Trial: NCT04193982
Drug: Saroglitazar
RxNorm normalized name: Saroglitazar
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives Saraglitazar 4mg once daily
Trial: NCT04193982
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receive Vitamin E 400mg twice daily after food for 6 months
Trial: NCT06133062
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
Trial: NCT04946825
Drug: Nicotine replacement therapy patch
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
Trial: NCT04946825
Drug: Nicotine replacement therapy lozenge
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
Trial: NCT06215716
Drug: Efruxifermin
RxNorm normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04926324
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Trial: NCT04926324
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
Trial: NCT05528952
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
Trial: NCT05528952
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
Trial: NCT05528952
Drug: UCPVax
RxNorm normalized name: UCPVax
DrugBank: UCPVax (DB17509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
Trial: NCT06379984
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual buprenorphine
Trial: NCT05593328
Drug: Onvansertib
RxNorm normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05593328
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04999202
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
Trial: NCT05503043
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
Trial: NCT06274879
Drug: Gemcitabin, Cisplatin and Durvalumab
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
Trial: NCT05701527
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
Trial: NCT05045183
Drug: Antibiotic Ointment
RxNorm normalized name: CVS Antibiotic Ointment
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the randomized wound site, a antibiotic ointment will be applied.
Trial: NCT05045183
Drug: Antiseptic Wash
RxNorm normalized name: CVS First Aid Antiseptic Wash
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the randomized wound site, a antiseptic wash will be applied.
Trial: NCT05323175
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthesia injected under ultrasound guidance
Trial: NCT05134584
Drug: Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 290μg once daily, 4 weeks
Trial: NCT05134584
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mL once daily, 4 weeks
Trial: NCT05134584
Drug: Omeprazol
RxNorm normalized name: Omeprazol
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg twice daily for the first 10 days
Trial: NCT05134584
Drug: Itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg three times daily for the first 10 days
Trial: NCT05814016
Drug: Danavorexton
RxNorm normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danavorexton IV infusion.
Trial: NCT05022459
Drug: Emicizumab
RxNorm normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
Trial: NCT05022459
Drug: FVIII
RxNorm normalized name: BDDrFVIII
DrugBank: MaxAdFVIII (DB17713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A